Edwards Lifesciences Co. (NYSE:EW) Shares Sold by BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp

BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp lessened its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 12.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 100,535 shares of the medical research company’s stock after selling 14,632 shares during the quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp’s holdings in Edwards Lifesciences were worth $6,634,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. First Community Trust NA acquired a new stake in shares of Edwards Lifesciences during the 2nd quarter worth $29,000. Prospera Private Wealth LLC acquired a new stake in Edwards Lifesciences during the third quarter worth about $32,000. Avior Wealth Management LLC raised its holdings in shares of Edwards Lifesciences by 138.7% in the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock worth $35,000 after purchasing an additional 308 shares during the period. Webster Bank N. A. acquired a new position in shares of Edwards Lifesciences in the 2nd quarter valued at about $39,000. Finally, Peoples Bank KS purchased a new stake in shares of Edwards Lifesciences during the 3rd quarter worth about $40,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analyst Ratings Changes

Several research firms have issued reports on EW. Truist Financial decreased their price objective on shares of Edwards Lifesciences from $71.00 to $70.00 and set a “hold” rating for the company in a research note on Friday, October 25th. Oppenheimer reiterated an “outperform” rating and issued a $90.00 price target on shares of Edwards Lifesciences in a report on Thursday, September 12th. Sanford C. Bernstein raised Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research report on Monday, October 28th. JPMorgan Chase & Co. upped their target price on Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a research report on Friday, October 25th. Finally, Jefferies Financial Group downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating and dropped their target price for the company from $85.00 to $70.00 in a report on Wednesday, September 18th. Seventeen equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $77.25.

Insider Buying and Selling

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $66.77, for a total transaction of $333,850.00. Following the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at $3,133,916.72. The trade was a 9.63 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Larry L. Wood sold 25,000 shares of the company’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the completion of the sale, the insider now directly owns 198,526 shares of the company’s stock, valued at $13,084,848.66. The trade was a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 40,000 shares of company stock valued at $2,657,000 over the last quarter. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Down 1.1 %

Shares of Edwards Lifesciences stock opened at $70.53 on Tuesday. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The company has a market capitalization of $41.60 billion, a P/E ratio of 10.18, a PEG ratio of 4.01 and a beta of 1.12. The business’s fifty day moving average price is $68.10 and its two-hundred day moving average price is $75.05. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, hitting the consensus estimate of $0.67. The business had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The company’s quarterly revenue was up 8.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.59 earnings per share. As a group, research analysts forecast that Edwards Lifesciences Co. will post 2.57 EPS for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.